PartnershipsThe partnership with Ascensia Diabetes Care now markets E365 to more than 2,400 annual prescribers, with the majority being new prescribers.
Patient Base GrowthThe approval of the Eversense 365 continuous glucose monitor system drove a 56% increase in patient base in 2024 over 2023 to approximately 6,000 global patients.
Product ApprovalEversense 365 is the first and only 365-day integrated continuous glucose monitoring (CGM) system approved by the FDA for people with Type 1 and Type 2 diabetes aged 18 years and older.